These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27473466)

  • 1. [Part II. Combination statin plus fibrate regimens (free and fixed)].
    Clin Investig Arterioscler; 2016 Jul; 28 Suppl 3():11-9. PubMed ID: 27473466
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis.
    Wierzbicki AS; Morrell J; Hemsley D; McMahon Z; Crook MA; Wray R
    Curr Med Res Opin; 2010 Sep; 26(9):2141-6. PubMed ID: 20662558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
    Alford JC; Saseen JJ; Allen RR; Nair KV
    Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin-fibrate combination for mixed dyslipidaemia: a limited option?
    Athyros VG; Tziomalos K; Karagiannis A; Mikhailidis DP
    Curr Med Res Opin; 2010 Sep; 26(9):2137-40. PubMed ID: 20662560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reasons for a combination].
    Núñez-Cortés JM
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():40-1. PubMed ID: 25043547
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias.
    Suh HS; Hay JW; Johnson KA; Doctor JN
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):470-84. PubMed ID: 22461130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
    Moutzouri E; Kei A; Elisaf MS; Milionis HJ
    Vasc Health Risk Manag; 2010 Aug; 6():525-39. PubMed ID: 20730069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?
    Milionis H
    Expert Opin Drug Saf; 2014 Mar; 13(3):267-9. PubMed ID: 24512564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 13. Physician variation in the de-adoption of ineffective statin and fibrate therapy.
    Everhart A; Desai NR; Dowd B; Herrin J; Higuera L; Jeffery MM; Jena AB; Ross JS; Shah ND; Smith LB; Karaca-Mandic P
    Health Serv Res; 2021 Oct; 56(5):919-931. PubMed ID: 33569804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gastroenterological aspects of atherosclerosis].
    Zvenigorodskaia LA; Samsonova NG; Efremov LI; Cherkashova EA; Lazebnik LB
    Eksp Klin Gastroenterol; 2011; (2):31-6. PubMed ID: 21560640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do persons with stroke benefit from statin-fibrate combination therapy?
    Castilla-Guerra L; Fernandez-Moreno Mdel C
    Eur J Intern Med; 2015 Mar; 26(2):148-9. PubMed ID: 25620642
    [No Abstract]   [Full Text] [Related]  

  • 16. [Part I. Fibrates in primary and secondary prevention].
    Clin Investig Arterioscler; 2016 Jul; 28 Suppl 3():3-10. PubMed ID: 27473465
    [No Abstract]   [Full Text] [Related]  

  • 17. Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low.
    Athyros VG; Wierzbicki AS
    Curr Med Res Opin; 2014 Jan; 30(1):57-8. PubMed ID: 24160920
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.
    Choi HD; Shin WG; Lee JY; Kang BC
    Vascul Pharmacol; 2015; 65-66():23-30. PubMed ID: 25451563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Achievement of therapeutic objectives].
    Mantilla T
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():20-4. PubMed ID: 25043543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All at sea: new lipid-lowering drug trials continue to disappoint.
    Wierzbicki AS
    Int J Clin Pract; 2013 Jul; 67(7):595-8. PubMed ID: 23758438
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.